Belite Bio Inc ADR (BLTE)

$116.72 +4.31 (3.83%)
Market Cap 3.72B
Revenue (ttm) 0.00
Net Income (ttm) -36.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 58,900
Avg Vol 76,676
Day's Range N/A - N/A
Shares Out 31.84M
Stochastic %K 65%
Beta -1.42
Analysts Strong Sell
Price Target $106.25

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 246 6240
Address:
12750 High Bluff Drive, Suite 475, San Diego, United States
SqueezeChronometer
SqueezeChronometer Nov. 2 at 11:03 AM
Next major retail squeeze candidate right here $BLTE $BCRX $SHW $NVS <
0 · Reply
Doozio
Doozio Oct. 31 at 12:54 PM
$BLTE on a FRYday during 🐒🍌🧠⏰♾️?
1 · Reply
topstockalerts
topstockalerts Oct. 17 at 1:29 PM
$BLTE setting up nicely....
0 · Reply
Christyatmond
Christyatmond Oct. 16 at 10:56 AM
$BLTE
0 · Reply
justiceforb_85
justiceforb_85 Oct. 9 at 1:53 AM
$BLTE curious as to whether there's significant upside to a positive P3 for tinlarebant? Current valuation is pretty high...
0 · Reply
Doozio
Doozio Oct. 4 at 8:48 PM
$BLTE out of the tightness it’s faatch 💣 or….
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:03 AM
$BLTE Outstanding article that hits the mark on BLTE's current state. So if you want to refresh your BLTE insights or learn about BLTE from scratch, this is a must read. https://beyondspx.com/quote/BLTE/analysis/belite-bio-unlocking-retinal-health-with-a-novel-oral-approach-nasdaq-blte
1 · Reply
SilverEagle
SilverEagle Oct. 2 at 6:22 PM
$BLTE looks ripe for a hulk candle
0 · Reply
Doozio
Doozio Sep. 26 at 12:49 PM
$BLTE it was always 🐒🍌🧠⏰♾️ but yo need them huckleberries back for Roger to get into that gap $EXEL again n $SEZL them 🐑 TTWO get NUTX
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:02 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BLTE $SOC $LYFT $UBER $AMSC l
0 · Reply
Latest News on BLTE
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 6:11 PM EST - 6 days ago

Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript

Nov 4, 2025, 12:36 PM EST - 12 days ago

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Oct 29, 2025, 8:35 AM EDT - 18 days ago

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Oct 29, 2025, 8:00 AM EDT - 18 days ago

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Sep 12, 2025, 8:00 AM EDT - 2 months ago

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:36 PM EDT - 3 months ago

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 11, 2025, 6:00 AM EDT - 3 months ago

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Belite Bio Announces Registered Direct Offering of $15 Million

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Jul 2, 2025, 3:00 AM EDT - 4 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

May 21, 2025, 3:00 AM EDT - 6 months ago

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

May 15, 2025, 11:53 AM EDT - 6 months ago

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:59 AM EDT - 6 months ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:00 PM EDT - 6 months ago

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

May 12, 2025, 8:35 AM EDT - 6 months ago

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

Belite Bio to Participate in Four Upcoming Investor Conferences

May 12, 2025, 8:00 AM EDT - 6 months ago

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:40 PM EDT - 8 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 17, 2025, 6:00 AM EDT - 8 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 17, 2025, 6:00 AM EDT - 8 months ago

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 3:00 AM EDT - 8 months ago

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Nov 27, 2024, 3:00 AM EST - 1 year ago

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:28 PM EST - 1 year ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Nov 5, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Nov 3, 2024, 4:00 PM EST - 1 year ago

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Sep 1, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 10:35 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 9, 2024, 4:30 PM EDT - 1 year ago

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Aug 5, 2024, 7:10 PM EDT - 1 year ago

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Jun 12, 2024, 2:55 AM EDT - 1 year ago

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 9:50 PM EDT - 1 year ago

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 6, 2024, 8:15 AM EDT - 1 year ago

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 6, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 1, 2024, 4:15 PM EDT - 1 year ago

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Belite Bio Announces $25 Million Registered Direct Offering

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:53 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 11, 2024, 10:28 PM EDT - 1 year ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 9:27 PM EDT - 1 year ago

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 8:00 AM EST - 2 years ago

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 20, 2023, 8:00 AM EST - 2 years ago

Belite Bio to Participate in the BTIG Ophthalmology Day

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 11:30 PM EST - 2 years ago

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

SqueezeChronometer
SqueezeChronometer Nov. 2 at 11:03 AM
Next major retail squeeze candidate right here $BLTE $BCRX $SHW $NVS <
0 · Reply
Doozio
Doozio Oct. 31 at 12:54 PM
$BLTE on a FRYday during 🐒🍌🧠⏰♾️?
1 · Reply
topstockalerts
topstockalerts Oct. 17 at 1:29 PM
$BLTE setting up nicely....
0 · Reply
Christyatmond
Christyatmond Oct. 16 at 10:56 AM
$BLTE
0 · Reply
justiceforb_85
justiceforb_85 Oct. 9 at 1:53 AM
$BLTE curious as to whether there's significant upside to a positive P3 for tinlarebant? Current valuation is pretty high...
0 · Reply
Doozio
Doozio Oct. 4 at 8:48 PM
$BLTE out of the tightness it’s faatch 💣 or….
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:03 AM
$BLTE Outstanding article that hits the mark on BLTE's current state. So if you want to refresh your BLTE insights or learn about BLTE from scratch, this is a must read. https://beyondspx.com/quote/BLTE/analysis/belite-bio-unlocking-retinal-health-with-a-novel-oral-approach-nasdaq-blte
1 · Reply
SilverEagle
SilverEagle Oct. 2 at 6:22 PM
$BLTE looks ripe for a hulk candle
0 · Reply
Doozio
Doozio Sep. 26 at 12:49 PM
$BLTE it was always 🐒🍌🧠⏰♾️ but yo need them huckleberries back for Roger to get into that gap $EXEL again n $SEZL them 🐑 TTWO get NUTX
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:02 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BLTE $SOC $LYFT $UBER $AMSC l
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Buy with a target price of 100 → 98.
0 · Reply
jlsnet22
jlsnet22 Sep. 12 at 12:54 PM
$BLTE https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-completion-dragon-2-year-phase-3-trial-oral/
0 · Reply
DonCorleone77
DonCorleone77 Sep. 8 at 12:33 PM
$BLTE Belite Bio announces up to $250M upsized private placement financing
0 · Reply
waterlock
waterlock Sep. 4 at 2:02 AM
$BLTE Does any know what fellow eyes represents in their DRAGON study? I checked their clinical trial info, doesn’t see anything saying fellow eyes specifically. I assume it is the placebo group. But, In their interim trial, BCVA shows that treated eyes has (almost) the same results as fellow eyes. I kinda assumed that the treated eyes should have BETTER corrected vision and not just the same? I assumed fellow eyes should have deteriorated BCVA. Can someone help here?
2 · Reply
ChartCortex
ChartCortex Aug. 23 at 7:40 AM
$BLTE Belite Bio Inc is a clinical stage ophthalmology company with regulatory milestones ahead
0 · Reply
JarvisFlow
JarvisFlow Jul. 3 at 11:30 AM
HC Wainwright & Co. has updated their rating for Belite Bio ( $BLTE ) to Buy with a price target of 100.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 2 at 9:58 AM
$BLTE Belite Bio completes enrollment in PHOENIX trial Belite Bio announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phase 3 pivotal trial evaluating the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with geographic atrophy in dry age-related macular degeneration.
0 · Reply
waterlock
waterlock Jun. 25 at 1:59 AM
$BLTE bad news for BLTE https://www.fiercebiotech.com/biotech/sanofi-backed-splicebio-secures-135m-series-b-eye-disease-gene-therapy-trials
1 · Reply
swingingtech
swingingtech Jun. 6 at 9:37 PM
$BLTE https://wallstreetwaves.com/blte-experiences-significant-drop-below-essential-moving-average/
0 · Reply
justiceforb_85
justiceforb_85 Jun. 6 at 7:50 PM
$BLTE adding on this dip.
0 · Reply
justiceforb_85
justiceforb_85 May. 22 at 3:44 AM
$BLTE tinlarebant promising in Stargardt disease. However, appears P3 trial is in Japanese patients which will raise a significant concern with FDA. Are there any studies being conducted in US patients?
1 · Reply